Journey Medical Revenue Growth Rates (DERM), Current and Historic Growth - CSIMarket
CSIMarket Company Name, Ticker, Suppliers, else..
 


• Revenue Y/Y
• Op. Income Y/Y
• Cop. Income Y/Y
• Net Income Y/Y
• Eps Cop. Y/Y
• Eps Net Y/Y
• Free Cash Flow Y/Y
• Cash Flow Y/Y
• Capex Y/Y
• Sales Y/Y Annual
Journey Medical Corp  (NASDAQ: DERM)
 

DERM's Revenue Growth by Quarter and Year

Journey Medical's Revenue results by quarter and year



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

DERM Revenue (in millions $) FY 2026 FY 2025 FY 2024 FY 2023
4th Quarter December -
3rd Quarter September -
2nd Quarter June 18.51
1st Quarter March 15.96
FY 34.47

DERMs Annual Revenue
Journey Medical's Revenue in the fiscal year 2025 $ 61.86 millions
Journey Medical's Revenue in the fiscal year 2024 $ 56.13 millions
Journey Medical's Revenue in the fiscal year 2023 $ 79.18 millions
Journey Medical's Revenue in the fiscal year 2022 $ 73.67 millions
Journey Medical's Revenue in the fiscal year 2021 $ 63.13 millions




DERM Revenue second quarter 2026 Y/Y Growth Comment
Journey Medical Corp reported Revenue improvement of 23.32% year on year in the second quarter 2026, to $ 18.51 millions, this is lower than Journey Medical Corp's recent average Revenue surge of 212.8%.

Looking into second quarter 2026 results within Major Pharmaceutical Preparations industry 78 other companies have achieved higher Revenue growth. While Journey Medical Corp' s Revenue rise of 23.32% ranks overall at the positon no. 908 in the second quarter 2026.


DERM Revenue ( Y/Y Growth %) 2026
 2025 2024 2023
4th Quarter December - 18.06 % -10.75 % -4.45 %
3rd Quarter September - 20.51 % -57.64 % 114.27 %
2nd Quarter June 23.32 % 1.01 % -13.45 % -6.12 %
1st Quarter March 21.46 % 0.84 % 6.72 % -47.6 %
FY   - 10.19 % -29.1 % -

Financial Statements
Journey Medical's second quarter 2026 Revenue $ 18.51 millions DERM's Income Statement
Journey Medical's second quarter 2025 Revenue $ 15.01 millions Quarterly DERM's Income Statement


DERM Revenue (Quarter on Quarter Growth %)

 2026
 2025 2024 2023
4th Quarter December - -8.79 % -6.9 % -55.82 %
3rd Quarter September - 17.46 % -1.55 % 101.16 %
2nd Quarter June 15.98 % 14.23 % 14.04 % 40.62 %
1st Quarter March -0.75 % -3.52 % -14.61 % -23.54 %
FY (Year on Year)   - 10.19 % -29.1 % -


Back to DERM Growth rate Comparisons >> Back to DERM Growth rate Comparisons >>


Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #79
Healthcare Sector #186
Overall #908

Revenue Y/Y Growth Statistics
High Average Low
3566.04 % 212.8 % -100 %
(Mar 31 2019)   (Jun 30 2021)
Revenue second quarter 2026 Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #79
Healthcare Sector #186
Overall #908
Revenue Y/Y Growth Statistics
High Average Low
3566.04 % 212.8 % -100 %
(Mar 31 2019)   (Jun 30 2021)

Revenue by Quarter for the Fiscal Years 2023, 2024, 2025, 2026

Journey Medical's Q/Q Revenue Growth


Revenue Q/Q Growth Statistics
High Average Low
18778.99 % 977.38 % -100 %
(Dec 31 2016)  


DERM's II. Quarter Q/Q Revenue Comment
Journey Medical Corp achieved in the II. Quarter 2026 below company average Revenue jump of 15.98% quarter on quarter, to $ 18.51 millions.

Although the II. Quarter 2026 Revenue Q/Q growth was lower than the regular , this has been yet encouraging story, as the II. Quarter surge, eclipses the 14.23% growth in the II. Quarter a year ago

Within Major Pharmaceutical Preparations industry 51 other companies have achieved higher Revenue quarter on quarter growth. While Journey Medical's Revenue growth quarter on quarter, overall rank is 609.


Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #52
Healthcare Sector #112
Overall #609
Revenue Q/Q Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry #52
Healthcare Sector #112
Overall #609
Revenue Q/Q Growth Statistics
High Average Low
18778.99 % 977.38 % -100 %
(Dec 31 2016)  


DERM's II. Quarter Q/Q Revenue Comment
Journey Medical Corp achieved in the II. Quarter 2026 below company average Revenue jump of 15.98% quarter on quarter, to $ 18.51 millions.

II. Quarter 2026 Revenue Q/Q growth were paradoxical, although lower than the regular, yet it demonstrates absolute recovery measured to the 14.23% in the II. Quarter a year ago.

Within Major Pharmaceutical Preparations industry 51 other companies have achieved higher Revenue quarter on quarter growth. While Journey Medical's Revenue growth quarter on quarter, overall rank is 609.


Journey Medical's 12 Months Revenue Growth Year on Year


Revenue TTM Growth

12 Months Ending
(Jun 30 2026)		 12 Months Ending
(Mar 31 2026)		 12 Months Ending
(Dec 31 2025)		 12 Months Ending
(Sep 30 2025)		 12 Months Ending
(Jun 30 2025)
Cumulative Revenue 12 Months Ending $ 68.18 $ 64.68 $ 61.86 $ 59.40 $ 56.40
Y / Y Revenue Growth (TTM) 20.89 % 15 % 10.2 % 2.82 % -27.4 %
Year on Year Revenue Growth Overall Ranking # 3437 # 3318 # 3004 # 2860 # 415
Seqeuential Revenue Change (TTM) 5.41 % 4.56 % 4.14 % 5.32 % 0.27 %
Seq. Revenue Growth (TTM) Overall Ranking # 2566 # 2442 # 2402 # 2840 # 2307


Cumulative Revenue growth Comment
Although Journey Medical's Annual Revenue growth year on year were below company's average 83.15% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 20.89% year on year, from 15% in Mar 31 2026.

In the Healthcare sector 466 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3318 to 3437.

Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 467
Overall # 3437

Revenue TTM Y/Y Growth Statistics
High Average Low
1078.91 %
 83.15 %
-34.79 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 374
S&P 500 # 2566
Cumulative Revenue growth Comment
Although Journey Medical's Annual Revenue growth year on year were below company's average 83.15% , Revenue announced in the Jun 30 2026 period, show improvement in Revenue trend, to cumulative trailing twelve month growth of 20.89% year on year, from 15% in Mar 31 2026.

In the Healthcare sector 466 other companies have achieved higher trailing twelve month Revenue growth. While Revenue growth total ranking has deteriorated compare to previous quarter from 3318 to 3437.


Revenue TTM Y/Y Growth Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 121
Healthcare Sector # 467
Overall # 3437

Revenue TTM Y/Y Growth Statistics
High Average Low
1078.91 %
83.15 %
-34.79 %
 


Revenue TTM Q/Q Growth Company Ranking
Within: No.
Industry # 121
Sector # 374
S&P 500 # 2566




Other Revenue Growth
Major Pharmaceutical Preparations Industry Revenue Growth Trends and Statistics
Healthcare Sector Revenue Growth Statistics
Revenue Growth Trends for overall market
DERM's Revenue Growth Ratio versus Major Pharmaceutical Preparations Industry, Healthcare Sector and total Market
Highest Ranking Revenue Growth
Lowest Ranking Revenue Growth




Companies with similar Revenue jump for the quarter ending Jun 30 2026 within Healthcare SectorY/Y Change %Revenue for the quarter ending Jun 30 2026
Vyne Therapeutics Inc 40.58%$ 40.580 millions
Qhslab Inc 39.98%$ 39.978 millions
Coherus Oncology inc 39.53%$ 39.526 millions
Neurocrine Biosciences Inc 39.49%$ 39.491 millions
Ss Innovations International Inc39.39%$ 39.393 millions
Assembly Biosciences Inc 38.94%$ 38.936 millions
Edap Tms Sa38.85%$ 38.847 millions
Picard Medical Inc 38.62%$ 38.620 millions
Hims and Hers Health Inc 38.41%$ 38.409 millions
Aquestive Therapeutics Inc 38.15%$ 38.149 millions
Mirum Pharmaceuticals Inc 37.92%$ 37.922 millions
Natera Inc 37.71%$ 37.715 millions
Zomedica Corp 36.59%$ 36.588 millions
Kura Oncology Inc 36.54%$ 36.538 millions
Scientific Industries Inc 36.02%$ 36.022 millions
Ceribell Inc 35.85%$ 35.852 millions
Intelligent Bio Solutions Inc 35.78%$ 35.777 millions
The Pennant Group Inc 35.76%$ 35.755 millions
Quanterix Corporation35.42%$ 35.416 millions
Inspiremd Inc 34.88%$ 34.882 millions
The Oncology Institute Inc 34.62%$ 34.624 millions
Agenus Inc34.36%$ 34.358 millions
Biodesix Inc 34.18%$ 34.184 millions
Myomo Inc 33.82%$ 33.819 millions
Ligand Pharmaceuticals Incorporated33.73%$ 33.733 millions
Biocryst Pharmaceuticals Inc 33.61%$ 33.606 millions
Biofrontera Inc 32.92%$ 32.924 millions
Ironwood Pharmaceuticals inc 32.62%$ 32.617 millions
Cadre Holdings inc 32.56%$ 32.561 millions
Supernus Pharmaceuticals inc 32.40%$ 32.399 millions


About Journey Medical Revenue Growth Rates (DERM), Current and Historic Growth - CSIMarket Analysis

How we calculate this

This page is based on issuer-reported fundamentals and CSIMarket’s U.S. equities database (20+ years). Growth is computed using year-over-year (Y/Y), sequential, and trailing-twelve-month (TTM) methods.

Last updated

  • Page updated:
  • Data lineage: SEC filings → XBRL parse → normalization CSIMarket.com Database → growth calculations.
  • Figures are derived from filed reports and may be restated; numbers are subject to revision.

Sources: the company’s SEC filings (XBRL/Inline XBRL) and CSIMarket.com’s normalization & QA processes.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.